NEA
NEA
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
1
$27K
Total Volume
$27K
1 transactions
Net Activity
$27K
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
No Recent Signal
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
NEA has an insider buy conviction of 0%, compared to the Unknown sector buy average of 50%.
Hamilton Michael S.
Portfolio Manager
$27K total
Over the last 90 days, corporate insiders at NEA (NEA) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 1 were sales. The total volume of insider trading reached $27K.
The net insider activity for NEA shows a net selling bias of $27K. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Hamilton Michael S. (Portfolio Manager), who traded 2.7K shares valued at $27K on Sep 24, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering NEA and the Unknown sector.
Tracking Insider Activity in Biotech: High Stakes and Hidden Signals
Biotech insiders possess unique asymmetric information, clinical results, FDA feedback, partnership negotiations. This guide explains how to track Form 4 activity at pre-commercial biotechs, what position sizes matter, and how to avoid false signals near data events.
Biotech Insider Buying: Analyzing Clinical Trial Catalysts
Biotech insiders walk a legal tightrope near trial readouts. This report identifies statistically significant buying clusters at small-cap biotechs 30-90 days before Phase 2 and Phase 3 data announcements.
How to Interpret Insider Buys in Distressed Debt Scenarios
When a company is near default, insider equity purchases are highly ambiguous. This guide explains how to read Form 4 buys in distressed situations, distinguishing rescue capital from genuine conviction versus contractual obligations.
FAQs About NEA Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for NEA.